Good morning. Elizabeth Cooney here in Boston filling in for Ed Silverman on a balmy August morning. Lots to catch up on today:

The Trump administration on Wednesday finalized long-sought rules for when Medicare will cover CAR-T treatments, often curative therapies that harness patients’ own immune cells against their cancer, STAT reports. Medicare will pay for CAR-T therapies even when used to treat conditions that aren’t FDA-approved. The two approved CAR-T treatments on the market are Yescarta from Gilead Sciences for non-Hodgkin lymphoma and Kymriah from Novartis for acute lymphoblastic leukemia.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy